Sign In
Section Navigation
Common TitleARIA
Official Title A Phase IIIb, Randomized, Open-label Study of the Safety and Efficacy of Dolutegravir/Abacavir/Lamivudine Once Daily Compared to Atazanavir and Ritonavir Plus Tenofovir/Emtricitabine Once Daily in HIV-1 Infected Antiretroviral Therapy Naïve Women
Phase Phase IIIB
ClinicalTrials.gov NCT01910402
Treatments
Dolutegravir-Abacavir-Lamivudine
Dolutegravir-Abacavir-Lamivudine Triumeq

Dolutegravir-Abacavir-Lamivudine

Tradename:TriumeqOther Names:DTG-ABC-3TCClass:Single-Tablet Regimens
Categories Pregnancy/WomenTreatment-Naive
Funding
IndustryViiV Healthcare
References
  • Orrell C, Hagins DP, Belonosova E, et al. Fixed-dose combination dolutegravir, abacavir, and lamivudine versus ritonavir-boosted atazanavir plus tenofovir disoproxil fumarate and emtricitabine in previously untreated women with HIV-1 infection (ARIA): week 48 results from a randomised, open-label, non-inferiority, phase 3b study. Lancet HIV. 2017;4:e536-e546.
    [PubMed Abstract]

Share by e-mail

Since you've received 80% or better on this quiz, you may claim continuing education credit.

You seem to have a popup blocker enabled. If you want to skip this dialog please Always allow popup windows for the online course.